Top Page
Sihuan Pharmaceutical Holdings Group
(0460)
Sihuan Pharmaceutical Holdings Group (0460) vs. iShares MSCI Hong Kong ETF (EWH)
Sihuan Pharmaceutical Holdings Group Business Overview & Revenue Model
Sihuan Pharmaceutical Holdings Group Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.10B | 1.90B | 1.86B | 2.18B | 3.04B | 2.46B |
| Gross Profit | 1.39B | 1.24B | 1.30B | 1.49B | 2.43B | 1.91B |
| EBITDA | -18.36M | -208.66M | 334.31M | -1.54B | 931.69M | 714.06M |
| Net Income | -80.64M | -216.66M | -54.02M | -1.91B | 416.51M | 473.38M |
Balance Sheet | ||||||
| Total Assets | 10.62B | 10.53B | 11.54B | 12.14B | 14.50B | 13.04B |
| Cash, Cash Equivalents and Short-Term Investments | 3.60B | 3.63B | 4.48B | 4.79B | 5.79B | 4.94B |
| Total Debt | 1.03B | 942.76M | 1.26B | 1.29B | 1.08B | 755.05M |
| Total Liabilities | 5.68B | 5.58B | 6.40B | 6.50B | 5.35B | 3.10B |
| Stockholders Equity | 4.38B | 4.37B | 4.43B | 4.74B | 8.28B | 9.19B |
Cash Flow | ||||||
| Free Cash Flow | 62.70M | 57.51M | -95.93M | -355.97M | 64.28M | -279.51M |
| Operating Cash Flow | 112.15M | 243.89M | 199.49M | 46.49M | 665.29M | 227.13M |
| Investing Cash Flow | 368.40M | 758.24M | 169.88M | -1.66B | -337.57M | -924.78M |
| Financing Cash Flow | -1.23B | -1.26B | -419.56M | -238.93M | 750.66M | 184.54M |
Sihuan Pharmaceutical Holdings Group Technical Analysis
Sihuan Pharmaceutical Holdings Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | HK$12.47B | 11.95 | 25.92% | 4.19% | 19.05% | 13.68% | |
| ― | HK$10.01B | 10.82 | 7.48% | 4.32% | 1.65% | -16.38% | |
| ― | $13.04B | 197.41 | -1.26% | 3.39% | -9.58% | -128.83% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $13.62B | ― | -1.87% | 0.72% | 19.21% | -115.91% | |
| ― | HK$13.55B | ― | -2.79% | ― | 29.21% | 80.37% |
Sihuan Pharmaceutical Holdings Group Corporate Events
Sihuan Pharmaceutical Holdings Group Ltd. has signed a cooperation agreement with U.S.-based Abalone Bio to jointly develop a new-generation innovative therapy for weight loss and muscle gain. This collaboration aims to advance research in targeting metabolism-related G protein-coupled receptors (GPCRs) to improve energy expenditure safely and effectively. The partnership leverages Abalone’s proprietary technology and Sihuan’s R&D resources to address current limitations in obesity treatments and enhance the company’s strategic position in the GPCR target field. This agreement marks a significant step in Sihuan’s strategy to deepen its involvement in the GPCR field, following its previous investment in DJS Antibodies.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. announced that its subsidiary, Xuanzhu Biopharm, has received Fast Track designation from the U.S. FDA for NG-350A, a treatment for mismatch repair-proficient locally advanced rectal cancer. This designation is significant as it expedites the development and approval process for drugs addressing unmet medical needs. NG-350A, developed in collaboration with Akamis Bio Ltd., is currently undergoing Phase Ib clinical trials and has shown promising results in safety and efficacy. This advancement strengthens Sihuan Pharmaceutical’s position in the oncology sector and highlights its commitment to addressing major clinical needs.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. announced a share repurchase of 15 million shares at an average price of HK$1.4505 per share, totaling approximately HK$21.76 million. This move is part of its strategic goal to enhance shareholder value and reflects its confidence in future growth. The company has seen significant progress in its medical aesthetics and innovative pharmaceuticals segments, with a notable revenue increase in its medical aesthetics business and the launch of several new products. These developments are expected to drive future revenue and profit growth, reinforcing Sihuan’s position in the industry.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. announced a share repurchase of 10 million shares, representing approximately 0.1089% of its total issued shares, at an average price of HK$1.5189 per share. This strategic move aligns with the company’s goal of enhancing shareholder value and reflects confidence in its future growth, particularly in its expanding medical aesthetics and innovative pharmaceuticals businesses. The company has seen significant growth in its medical aesthetics segment, with a revenue increase of 81% year-on-year, and has launched several new products, which are expected to drive future revenue and profit growth.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. announced the purchase of 9,255,000 shares as part of its 2022 Share Award Scheme, representing approximately 0.1009% of the total shares in issue. This move is part of the company’s strategic objective to strengthen its market position in the medical aesthetics and biopharmaceutical industries, potentially enhancing its operational capabilities and stakeholder value.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. has successfully completed the spin-off and separate listing of its subsidiary, Xuanzhu Biopharm, on the Main Board of the Stock Exchange of Hong Kong. The listing took place on October 15, 2025, marking a significant milestone for the company as it expands its presence in the biopharmaceutical sector, potentially enhancing its market positioning and providing new opportunities for stakeholders.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. announced the purchase of 10,000,000 shares as part of its 2022 Share Award Scheme. This transaction represents approximately 0.1089% of the total issued shares, excluding treasury shares. The purchase is part of the company’s strategic efforts to enhance its market position and align with its long-term business objectives in the pharmaceutical and medical aesthetics sectors.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. has made an equity investment in Swiss company Suisselle SA to strengthen its position in the global medical aesthetic market. This investment grants Sihuan permanent exclusive distribution rights for Suisselle’s CELLBOOSTER® skin booster products in China and enhances their collaboration to promote medical aesthetic products in Europe and other markets. The move aligns with Sihuan’s globalization strategy, complementing its previous acquisition of Genesis Biosystems in the U.S., and aims to create long-term sustainable value for shareholders.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. announced the publication of the prospectus for the proposed spin-off and separate listing of Xuanzhu Biopharm on the Main Board of the Hong Kong Stock Exchange. The global offering will include 67,333,500 H Shares, representing 13% of Xuanzhu Biopharm’s total issued share capital, with an expected offer price of HK$11.60 per share. The spin-off and listing are contingent upon approval from the Stock Exchange and market conditions, with no guarantee of proceeding, urging shareholders to exercise caution.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group has announced that its subsidiary, Meiyan Space, received approval from the National Medical Products Administration of China for its new skin booster product, Dongyan. This product, which combines hyaluronic acid sodium with L-carnosine and other components, is designed to improve skin dryness and dullness. The approval is a significant milestone for Meiyan Space, enhancing its strategic product matrix and strengthening its position in the medical aesthetics industry. The global skin booster market is projected to grow significantly, with the Chinese market expected to expand rapidly, driven by increasing consumer demand for skin health management. Meiyan Space plans to continue its investment in R&D and market penetration to provide advanced and personalized medical aesthetic services.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group announced a share repurchase of up to HK$500 million, with 1,500,000 shares already repurchased at an average price of HK$1.48 per share. This move aligns with the company’s strategic goals to strengthen its market position and shareholder value. The company has shown significant growth in its medical aesthetics and innovative pharmaceuticals segments, with a notable increase in revenue and the launch of several new products, which are expected to drive future growth.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. announced that its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd., has submitted a post-hearing information pack (PHIP) to the Hong Kong Stock Exchange in connection with its proposed spin-off and separate listing. The move is subject to approval by the Stock Exchange and other conditions, and if successful, it could lead to a preferential offering and a global offering. Stakeholders are advised to exercise caution as there is no guarantee that the spin-off and listing will proceed.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. has announced the basis of assured entitlement for qualifying shareholders in the preferential offering related to the proposed spin-off and separate listing of its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd., on the Hong Kong Stock Exchange. The entitlement is set at one reserved share for every 2,728 shares held as of the record date, with the spin-off subject to approval and market conditions. This move could potentially enhance the company’s market positioning by unlocking value through the separate listing of its biopharmaceutical arm.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group announced that its subsidiary, Huisheng Biopharmaceutical, has received approval for its innovative GLP-1R/GCGR dual target drug, P052 injection, for the treatment of type 2 diabetes and obesity. This approval highlights Huisheng Biopharmaceutical’s strong R&D capabilities and positions the company to capture significant market potential in the expanding diabetes treatment sector in China, where diabetes and obesity rates are rising. The P052 injection is expected to compete with existing treatments like Semaglutide, offering improved weight loss effects and enhancing the company’s competitiveness and market value in the diabetes industry.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. announced an update on the proposed spin-off and separate listing of its subsidiary, Xuanzhu Biopharm, on the Main Board of the Stock Exchange of Hong Kong Limited. The record date for determining the assured entitlement of qualifying shareholders to the SpinCo shares in the global offering is set for September 18, 2025. However, the proposed spin-off is subject to various conditions, including approval from the Stock Exchange and market conditions, and there is no assurance that it will proceed. Shareholders are advised to exercise caution, as the preferential offering will not proceed if the spin-off does not occur.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group announced a share repurchase plan, buying back 13,096,000 shares at an average price of HK$1.4945, reflecting their confidence in the company’s future. The company is experiencing significant growth in its medical aesthetics and innovative pharmaceuticals sectors, with a notable increase in revenue and the launch of new products, which are expected to drive future revenue and profit growth.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group has announced a strategic partnership with dProtein Pharmaceutical Biotechnology to establish an AI-driven R&D company focused on developing novel medical aesthetic products. This collaboration aims to leverage AI technology to innovate high-end medical aesthetic raw materials, reduce costs, and enhance efficiency, thereby strengthening Sihuan’s competitive position in the medical aesthetics industry. The initiative is expected to address unmet market needs and boost the company’s long-term growth and market value.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. has announced a change in the composition of its Nomination Committee, with Ms. Chen Yanling, an existing executive director, appointed as a new member effective from September 1, 2025. This change is expected to enhance the effectiveness and diversity of the Board, thereby improving the company’s overall corporate governance practices.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. announced the composition of its board of directors and their roles within the company, effective from September 1, 2025. This announcement highlights the leadership structure and governance of the company, which could impact its strategic direction and reassure stakeholders about its management stability.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. has announced amendments to the terms of reference for its Nomination Committee, which was initially established in 2010. The committee is responsible for reviewing the board’s structure and composition, ensuring it aligns with the company’s corporate strategy. The changes aim to enhance governance by ensuring a diverse and independent board, which could impact the company’s strategic direction and stakeholder confidence.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. reported a 20.7% increase in total revenue for the first half of 2025, driven by substantial growth in its medical aesthetics business, which saw an 81.3% rise due to strategic expansions and marketing upgrades. While the generic medicine segment experienced a decline, the innovative medicine sector showed a significant increase, contributing to an overall gross profit margin improvement to 66.1%. The company’s R&D expenses decreased as core projects reached commercial application, indicating a shift towards a more profitable phase.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. has announced an interim cash dividend of RMB 0.0099 per share for the six months ending June 30, 2025. The dividend will be paid in Hong Kong dollars at a rate of HKD 0.0109 per share, with an ex-dividend date set for September 26, 2025, and a payment date of October 10, 2025. This announcement reflects the company’s financial performance and commitment to providing returns to its shareholders, potentially enhancing its market position and investor confidence.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group’s subsidiary, Xuanzhu Biopharm, has received drug registration approval from China’s National Medical Products Administration for its innovative drug, Dirozalkib Tablets, aimed at treating ALK-positive advanced non-small cell lung cancer. This approval marks a significant milestone in Xuanzhu Biopharm’s R&D pipeline, offering a breakthrough treatment option with notable clinical advantages, including rapid action, superior efficacy, and improved safety profile. The drug is expected to enhance the quality of life for patients and support the ‘Healthy China 2030’ cancer prevention and control goals, amidst a growing market for ALK inhibitors in China.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
Sihuan Pharmaceutical Holdings Group Ltd. has announced a board meeting scheduled for August 29, 2025, to approve the interim results for the first half of the year and discuss the potential payment of an interim dividend. This meeting is significant as it will provide insights into the company’s financial health and strategic decisions, potentially impacting its market position and stakeholder interests.
Sihuan Pharmaceutical Holdings Group announced that its subsidiary, Huisheng Biopharmaceutical, has had its new drug application for Semaglutide Injection accepted by the National Medical Products Administration. This development marks a significant milestone in the company’s R&D efforts in diabetes treatment, potentially enhancing its competitive position in the market. With diabetes being a major focus area, the acceptance of Semaglutide Injection, a GLP-1 receptor agonist, underscores Huisheng’s commitment to expanding its diabetes treatment portfolio and addressing the growing diabetes prevalence in China.
Sihuan Pharmaceutical Holdings Group Ltd. has announced a positive profit alert, expecting to achieve a revenue of not less than RMB1,100 million and a net profit of not less than RMB50 million for the first half of 2025. This growth is driven by a significant increase in the medical aesthetics business, the successful commercialization of new innovative drugs, and a narrowing decline in the generic drug sector. The company has received approvals for 41 new products, which are anticipated to boost future revenue and profit growth.